Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

February 28, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

arsenic trioxide

DRUG

dexamethasone

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

30322

Winship Cancer Institute of Emory University, Atlanta

34689

Pasco Pinellas Cancer Center - Tarpon Springs, Tarpon Springs

72764

Highlands Oncology Group - Springdale, Springdale

76104

Texas Cancer Care, Fort Worth

80218

Rocky Mountain Cancer Centers - Midtown, Denver

83642

Mountain States Tumor Institute - Boise, Meridian

85712

Arizona Clinical Research Center, Tucson

95204

Stockton Hematology Oncology Medical Group, Stockton

92868-3849

St. Joseph Hospital Regional Cancer Center - Orange, Orange

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

CTI BioPharma

INDUSTRY